Insmed Inc (INSM)vsProtagonist Therapeutics Inc (PTGX)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
PTGX
Protagonist Therapeutics Inc
$104.31
+3.90%
HEALTHCARE · Cap: $6.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 1218% more annual revenue ($606.42M vs $46.02M). INSM leads profitability with a -2.1% profit margin vs -282.8%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
PTGX
Avoid28
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Earnings expanding 351.3% YoY
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Trading at 10.6x book value
ROE of -20.2% — below average capital efficiency
Revenue declined 95.6%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : PTGX
The strongest argument for PTGX centers on EPS Growth.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : PTGX
The primary concerns for PTGX are Price/Book, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
PTGX carries more volatility with a beta of 2.24 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
PTGX generates stronger free cash flow (-38M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 28/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Protagonist Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?